SharpEye
SharpEye, SAS created in 2020, aims to develop an innovative medical device imaging the cells of the eye for improved diagnosis of various pathologies: old age, diabetic retinopathy, vascular occlusions, hereditary and inflammatory diseases.
Faced with the increase in ocular pathologies due to the aging of the population and our lifestyle habits, and a better understanding of the numerous mechanisms of these pathologies, the new company SharpEye is developing a revolutionary ophthalmic imaging tool allowing earlier diagnosis and precise and personalized monitoring of patients.
Successfully launched during confinement, this start-up is the result of a collaboration between the Vision Institute and the Langevin Institute, set up by the ERC Synergy Helmholtz project (2014-2020, PIs José Sahel and Mathias Fink).
Establishment: ESPCI Paris - PSL, University of Paris, Sorbonne University, CNRS
Laboratory: Langevin Institute
Co-founders: Kate Gieve, Michel Paques, José Sahel (Hôpital des Quinze Vingts); Claude Boccara, Viacheslav Mazlin and Mathias Fink (Langevin Institute).
CEO: Jerome Martinez
